Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 non-inferiority trial of human fibrinogen for acquired hypofibrinogenemia in chronic liver disease
CTR20234075Phase 3Completed
- Sponsor
- Tonrol Biopharmaceuticals
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Fibrinogen human in Acquired fibrinogenopenia, chronic liver disease (CLD), sponsored by Tonrol Biopharmaceuticals. Started May 2024; status: completed.
02
Drugs
Fibrinogen human
03
Conditions
Acquired fibrinogenopeniachronic liver disease (CLD)
Beyond the preview
Go deeper on CTR20234075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234075.